Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
SPECIALISED THERAPEUTICS LIMITED,Ripretinib,For people with advanced metastatic or unresectable GIST who have experienced disease progression following treatment with imatinib and sunitinib,Ripretinib (QINLOCKÂ®),Options for investment,Community and Hospital,Oncology Agents and Immunosuppressants
